Chenguang Biotech Group

Chenguang Biotech has released its 2026 interim report, showing net profit attributable to the parent company of 179 million yuan, a decrease of 16.95% compared with the same period last year. Total operating revenue was 3.159 billion yuan, down 13.63% year-on-year. Net cash inflow from operating activities was 1.218 billion yuan, down 33.43% year-on-year. The latest asset-liability ratio was 64.06%, gross margin was 13.46%, return on equity was 5.25%, and diluted earnings per share was 0.37 yuan.

Chenguang Biotech Group was ordered by the Xinjiang Securities Regulatory Bureau to rectify and was issued a warning letter after a subsidiary's non-operating fund occupation of 136 million yuan. Between March and April 2025, the company received a total of 136 million yuan in intercompany loans from a wholly owned subsidiary of Xinjiang Shengyuan Biotechnology, a consolidated entity, and from Handan Chenguang Plant Protein. The funds were repaid with interest in May, constituting non-operating fund occupation. Xinjiang Shengyuan Biotechnology and its subsidiaries are entities within the company's consolidated statements, and on a look-through basis the company holds an 89.82 percent stake in it. The Xinjiang Securities Regulatory Bureau required the company to submit a written rectification report within 30 days and said the relevant measures will be recorded in the securities and futures market integrity archive. The company said it attaches great importance to the matter and will strengthen internal controls and financial management, adding that the measures do not affect normal production and operations.